Document is current

Article History

Received: 1 March 2024

Accepted: 28 March 2024

First Online: 4 May 2024

Declarations

:

: R.S.B. has received honoraria as speaker: Novartis, AstraZeneca, MSD, Lilly, GSK, Clovis, Seagen, Pfizer, Roche, and Gilead Oncology, Advisory fees: Novartis, Lilly, GSK, Seagen, and Roche, and Non-financial disclosure: ESMO Young Oncologists Committee Member and Scientific Secretary of the Spanish Society of Medical Oncology; A.L.S. has received a speaker honorarium from Pfizer, Novartis, Daiichi-Sankyo, MSD, and Accord; Y.J.G. has received speaker honoraria from Roche, Novartis, Pfizer and Daiichi and travel grants from Roche, Novartis, Pfizer, and Daiichi and Gilead; A.S.T. declares no conflict of interest; M.A. has received a speaker honorarium from Novartis, Pfizer, Lilly, Gilead, and AstraZeneca; I.E.D.G. has received a speaker honorarium from Pfizer, Novartis, Lilly, Gilead, AstraZeneca, and Daiichi-Sankyo; F.M. has received consultancy/speaker fees from Novartis, Roche, Pfizer, Astra Zeneca, Daiichi-Sankyo, Gilead, Exact Sciences, Seagen, and Pierre Fabre and Institution research funding from Pfizer, Travel support from Pfizer, Pierre Fabre, and Gilead; P.T. is a Consultant or played Advisory Role in AstraZeneca, Daiichi-Sankyo, Novartis, Roche, Adamed, and Seagen, Speaker honorarium: Pfizer, MSD, Novartis, Lilly, AstraZeneca, Daiichi-Sankyo, and Seagen, Travel grants: Pfizer, AstraZeneca, Novartis, and GSK, and Research funding: Seagen; B.H.L. has received a speaker honorarium from Roche, Novartis, PharmaMar, Eisai, Pfizer, Teva, Kyowa Kirin, AstraZeneca, GSK, Daiichi-Sankyo, and Gilead as well as travel/educational grants from Roche, Pfizer, Novartis, Merck, Kyowa Kirin, Pierre Fabre, and Lilly; A.L. has received financial support for attending symposia and speaker honorarium from Eli Lilly & Co. and Novartis, which is not relevant to this study; L.L. declares no conflict of interest; S.G.C. declares no conflict of interest; A.M. has received honoraria from AstraZeneca, Clovis, GSK, MSD, and PharmaMar; S.L.T. has not received research grants to disclose nor owns stocks to disclose, speaker honorarium from Lilly, advisory role for AstraZeneca, Daiichi-Sankyo, Gebro Pharma, Gilead, GSK, Lilly, Menarini_Stemline, Novartis, Pfizer, Pierre Fabre, Roche, and Seagen and is a member of board of directors of SEOM and GEICAM; L.M. has received a speaker honorarium from Novartis; C.B. has received speakers’ honoraria: Roche, Novartis, Lilly, Daiichi AstraZeneca, and GSK, travel grant: Roche, Novartis, and Pfizer; J.A.G.S. declares consultative and advisory services for Seagen, AstraZeneca, Daiichi-Sankyo, Novartis, Gilead, and Menarini, Consultancy/speaker fees from Celgene, Eli Lilly, EISAI, MSD, Exact Sciences, Tecnofarma, Nolver (Adium), Asofarma, and Roche, Institution and research funding from AstraZeneca, and Travel support from Gilead, AstraZeneca, and Daiichi-Sankyo; E.C. has received research grants from Roche and has received a speaker honorarium and Advisory Board meetings from Astra Zeneca-Daiichi-Sankyo, Roche, Pfizer, Novartis, MSD, Lilly, Gilead, and no owns stock in any company; M.M has received research grants from Roche, PUMA, and Novartis, consulting/advisory fees from AstraZeneca, Amgen, Taiho Oncology, Roche/Genentech, Novartis, PharmaMar, Eli Lilly, PUMA, Taiho Oncology, Daiichi-Sankyo, Menarini/Stemline, and Pfizer and speakers’ honoraria from AstraZeneca, Lilly, Amgen, Roche/Genentech, Novartis, and Pfizer.

: This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of <i>Hospital Universitario 12 de Octubre</i> (May 17th 2022/CEIm 22/206) and subsequently approved by each institutional Research Ethics Board.